Overview

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

Status:
Completed

Trial end date:
2016-12-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic patients.

Phase:

Phase 2

Details

Lead Sponsor:

Ocera Therapeutics
Ocera Therapeutics, Inc.

Treatments:

Phenylacetic acid